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disease was deﬁned as any clinical history of myocardial
infarction, percutaneous coronary intervention, coronary
artery bypass surgery, or angiographic evidence of coronary
artery disease (50% stenosis) in 1 major coronary artery.
Glycemic status and clinical deﬁnition of diabetes mellitus,
“prediabetes,” and nondiabetes were deﬁned by the latest
practice guidelines on the basis of fasting glucose and gly-
cosylated hemoglobin (HbA1c) levels (fasting glucose <100
mg/dl and HbA1c <5.7% for normal subjects; fasting
glucose 126 mg/dl or HbA1c 6.5% or currently taking
glucose-lowering medications for diabetes mellitus; neither
normal nor diabetes mellitus for prediabetes).7 Adjudicated
outcomes were ascertained over the ensuing 3 years for all
subjects after enrollment. The prospective determination of
clinical outcomes was made by the research personnel
contacting participants independent of study investigators,
with prespeciﬁed criteria and conﬁrmation by review of
documentation independent of the investigators. Major
adverse cardiovascular events (MACEs) were deﬁned as
death, nonfatal myocardial infarction, or nonfatal cerebro-
vascular accident after enrollment. Blood samples were
collected before the administration of heparin, placed on ice,
aliquoted, and frozen at 80F within 2 hours of collection.
All laboratory assays, including hsCRP, BNP, MPO,
apolipoprotein A1, apolipoprotein B100, and creatinine,
were performed using the Abbott ARCHITECT ci8200
platform (Abbott Diagnostics Inc., Abbott Park, Illinois).
The intra- and interassay coefﬁcients were 4% and 2.4% for
hsCRP, 2.6% and 3.5% for BNP, and 6.2% and 4.1% for
MPO, respectively.
Student’s t tests or Wilcoxon’s rank-sum tests for contin-
uous variables and chi-square tests for categorical variables
were used to examine the differences between the groups.
A cardiac biomarker score (CBS) was given to each group on
the basis of whether it had a positive value for each respective
biomarker. We used cutoffs for each of the 3 biomarkers
(BNP >100 pg/ml, hsCRP >2.0 ng/L, and MPO >322
pmol/L) on the basis of previous cutoffs used for the respective
markers, as reported in previous studies.2,4,8 Each of the groups
was categorized as 0, 1, 2, or 3 as a measure of how many
biomarkers were deemed positive, which was deﬁned as the












Age (yrs) 63  11 64  10 63  11 61  12 <0.001
Men 65% 61% 70% 64% <0.001
Hypertension 71% 78% 70% 62% <0.001
History of myocardial infarction 33% 35% 32% 32% <0.150
Systolic blood pressure (mm Hg) 133 (120e146) 134 (120e149) 132 (120e145) 132 (119e147) <0.015
Low density lipoprotein cholesterol (mg/dl) 95 (78e116) 95 (77e115) 97 (80e118) 94 (76e116) <0.012
High density lipoprotein cholesterol (mg/dl) 34 (28e41) 32 (27e39) 34 (28e42) 34 (29e42) <0.001
Creatinine clearance (ml/min/1.73 m2) 100 (76e126) 99 (74e128) 100 (77e126) 100 (79e126) <0.512
Cigarette smoking 65% 64% 68% 62% <0.002
Aspirin 73% 73% 74% 71% <0.357
b blockers 61% 65% 62% 56% <0.001
Angiotensin converting enzyme inhibitors
or angiotensin receptor blockers
50% 60% 47% 41% <0.001
Statins 59% 63% 59% 54% <0.001
hsCRP (mg/L) 2.00 (0.91e4.47) 2.56 (1.13e5.93) 1.89 (0.86e3.95) 1.67 (0.83e4.00) <0.001
BNP (pg/ml) 83 (34e200) 93 (40e240) 78 (32e177) 83 (32e198) <0.001
MPO (pmol/L) 103 (70e195) 105 (74e186) 104 (69e201) 100 (68e194) <0.199
Data are expressed as mean  SD, as percentages, or as median (interquartile range).
Table 2
Cox proportional hazards analyses for individual cardiac biomarker and
future major adverse cardiovascular events at 3 years
Variable Univariate Model Multivariate Model*
HR (95% CI) p Value HR (95% CI) p Value
BNP >100 pg/ml 2.76 (2.25e3.39) <0.001 2.10 (1.65e2.68) <0.001
hsCRP >2 ng/L 2.10 (1.71e2.58) <0.001 1.82 (1.46e2.28) <0.001
MPO >322 pmol/L 1.43 (1.12e1.82) <0.004 1.32 (1.02e1.71) <0.036
* Adjusted for age, gender, low density and high density lipoprotein
cholesterol, systolic blood pressure, former or current cigarette smoking,
diabetes mellitus, history of myocardial infarction, and creatinine clearance.
Figure 1. Kaplan Meier analysis of CBS predicting future MACEs at 3 year
follow up.
regression was used for time-to-event analysis to determine
hazard ratios (HRs) and 95% conﬁdence intervals (95%
CIs) for MACEs. Unadjusted trends for all-cause mortality
rates as well as rates of nonfatal myocardial infarction
or stroke with increasing quartiles of MPO, hsCRP, and
BNP were evaluated using the Cochran-Armitage test
using a time-to-event approach. Adjustments were made for
individual traditional cardiac risk factors (including age,
gender, low-density and high-density lipoprotein cholesterol,
systolic blood pressure, former or current cigarette smoking,
diabetes mellitus, apolipoprotein B100/apolipoprotein A1
ratio, history of myocardial infarction, and creatinine
clearance) to predict incident 3-year risk for MACEs. Net
reclassiﬁcation analysis was performed with the 2 Cox
models adjusted for traditional risk factors. Cutoff values for
net reclassiﬁcation index estimation used a ratio of 6:3:1 for
low-, medium-, and high-risk categories. All analyses were
performed using R version 8.02 (R Foundation for Statis-
tical Computing, Vienna, Austria), and p values <0.05 were
considered statistically signiﬁcant.
Results
Table 1 describes the baseline characteristics of our study
population and is stratiﬁed according to glycemic status.
The median levels of hsCRP, BNP, and MPO were
2.00 pg/ml (interquartile range 0.91 to 4.47), 83 pg/ml
(interquartile range 34 to 200), and 103 pmol/L (inter-
quartile range 70 to 195), respectively. All 3 biomarkers
were notably elevated in patients with diabetes compared to
those with prediabetes or nondiabetes.
Table 2 represents the prognostic value of individual
cardiac biomarkers in our study cohort. All 3 cardiac
biomarkers provided incremental risk prediction in our
study cohort. After adjusting for traditional risk factors,
including Framingham risk factors, log-transformed BNP,
hsCRP, and MPO each remained independent predictors of
incident MACEs at 3-year follow-up.
By summing the number of positive cardiac biomarkers,
we developed a CBS that integrated the risk proﬁle of our
study cohort. As illustrated in Figure 1, the CBS provided
incremental prognostic value, as displayed by Kaplan-Meier
analysis. As listed in Table 3, the CBS, based on the sum
total of positive biomarkers, provided independent predic-
tion of future risk for incident MACEs at 3 years (HR 7.61,
95% CI 4.98 to 11.65, p <0.001), even after adjustment for
traditional risk factors (HR 6.11, 95% CI 3.98 to 9.38,
p <0.001), in addition to apolipoprotein B100/apolipopro-
tein A1 ratio (HR 6.11, 95% CI 3.98 to 9.38, p <0.001)
(Table 3). The ability of the CBS to provide incremental risk
stratiﬁcation can be seen in subgroups of patients with
primary and secondary prevention, as well as those with
maximal coronary artery stenoses <50% and 50%
(Figure 2). A higher CBS predicted future risk for MACEs
at 3 years regardless of age, gender, body mass index, dia-
betes mellitus, hypertension, renal insufﬁciency, or previous
myocardial infarction (p <0.01 for all). Use of the CBS on
top of traditional risk factors was also shown to reclassify
subjects (net reclassiﬁcation index 12.86%, p <0.001;
integrated discrimination improvement 12.0%, p <0.001;
C-statistic 66.9% vs 71.1%, p <0.001).
We further analyzed our study cohort according to gly-
cemic status and different subgroups. The capability of the
CBS to stratify patients’ risk proﬁles within subjects with
diabetes mellitus, prediabetes, or normal glycemic status
(neither prediabetes nor diabetes) on the basis of practice
Table 3
Cox proportional hazards analyses of cardiac biomarker score stratiﬁed by glycemic status
Variable CBS
0 1 2 3
Whole cohort (n 3,635)
Unadjusted HR 1 2.59 (1.82e3.68)* 4.72 (3.33e6.69)* 7.61 (4.98e11.65)*
Adjusted HR, model 1 (95% CI) 1 2.27 (1.59e3.23)* 3.67 (2.58e5.24)* 6.11 (3.98e9.38)*
Adjusted HR, model 2 (95% CI) 1 2.27 (1.59e3.23)* 3.67 (2.58e5.24)* 6.11 (3.98e9.38)*
MACEs 39/955 159/1,549 173/959 47/172
Normal (n 1,014)
Unadjusted HR 1 1.78 (0.94e3.37) 3.23 (1.69e6.16)* 6.23 (2.9e13.37)*
Adjusted HR, model 1 (95% CI) 1 1.43 (0.74e2.75) 2.37 (1.21e4.64)* 4.73 (2.18e10.25)*
Adjusted HR, model 2 (95% CI) 1 1.36 (0.7e2.61) 2.23 (1.14e4.39)* 4.24 (1.96e9.18)*
MACEs 13/290 35/445 32/230 13/49
Prediabetes (n 1,529)
Unadjusted HR 1 2.74 (1.56e4.84)* 4.75 (2.7e8.38)* 10.27 (5.24e20.13)*
Adjusted HR, model 1 (95% CI) 1 2.4 (1.36e4.23)* 3.67 (2.06e6.54)* 7.87 (3.99e15.55)*
Adjusted HR, model 2 (95% CI) 1 2.37 (1.35e4.19)* 3.58 (2e6.41)* 7.62 (3.87e15.01)*
MACEs 15/427 61/654 61/379 20/69
Diabetes mellitus (n 1,092)
Unadjusted HR 1 3.17 (1.67e6)* 5.59 (2.98e10.49)* 6.16 (2.8e13.52)*
Adjusted HR, model 1 (95% CI) 1 3.06 (1.61e5.78)* 4.79 (2.55e9)* 5.59 (2.54e12.31)*
Adjusted HR, model 2 (95% CI) 1 3.05 (1.61e5.77)* 4.8 (2.55e9.01)* 5.61 (2.55e12.33)*
MACEs 11/238 63/450 80/350 14/54
Model 1 was adjusted for traditional risk factors, including age, gender, systolic blood pressure, low density lipoprotein cholesterol, high density lipoprotein
cholesterol, and smoking. Model 2 was adjusted for traditional risk factors plus apolipoprotein B100/apolipoprotein A1 ratio.
* p <0.001.
guidelines7 remained robust (Table 3, Figure 3). In a similar
manner, after adjustment for HbA1c, the prognostic value of
the CBS was preserved. Furthermore, the prognostic value
of the CBS was similar regardless of age, gender, body mass
index, diabetes mellitus, hypertension, renal insufﬁciency,
or previous myocardial infarction (p <0.01 for all).
Discussion
Although previous studies have examined similar multi-
marker strategies for risk prediction, many of them used
biomarkers that are not commonly used or available in the
clinical practice settings. The key ﬁnding in this study is the
incremental prognostic value of all 3 clinically available
plasma cardiac biomarkers beyond standard evaluation of
classic Framingham risk factors, renal function, and apoli-
poprotein B100/apolipoproteinA1 ratio in troponin-negative,
stable cardiac patients who undergo coronary angiography.
We further identiﬁed comparable prognostic value within
subsets of patients with prediabetes or nondiabetes or those
with no signiﬁcantly obstructive coronary artery disease,
further underscoring the potential for a multimarker approach
in identifying vulnerable patients within cohorts that may
allow targeted risk factor modiﬁcations and more aggressive
preventive interventions.
HsCRP is the most common systemic inﬂammatory
biomarker used in clinical practice, particularly in patients
with diabetes mellitus and potential response to statin
therapy.4,9 11 Elevated levels have also been associated
with altered cardiac structure and function, as well as
adverse long-term consequences.12 In addition, hsCRP has
been suggested to play a role in atherosclerosis and its
complications, although genetic studies suggest that the
association with adverse outcomes may not be causal.13,14
In contrast, MPO has been shown to directly promote the
catalytic consumption of nitric oxide, leading to the devel-
opment of endothelial dysfunction.15 17 MPO is a leuko-
cyte-derived hemoprotein that has been linked in the
development and subsequent instability of atherosclerotic
plaques.18,19 Previous studies have shown MPO to have
prognostic signiﬁcance in subjects with unstable angina, as
well as after acute myocardial infarction, acute heart failure,
and chronic stable heart failure, as well as healthy middle-
aged and elderly subjects.3,18,20 23 Recently, it was also
found that MPO remained a statistically signiﬁcant prog-
nostic indicator of cardiovascular risk in a large stable CAD
population.8 In contrast, the natriuretic peptide family is
a group of endogenous peptides primarily produced in the
heart that provide counter-regulatory effects on a wide range
of organs to maintain perfusion and reduce overloading
status of the vasculature.24 BNP has recently been shown to
be elevated in acute coronary syndromes without necessarily
having myocardial infarction, and it may reﬂect not only the
underlying impairment of left ventricular function but also
the severity of the ischemic episode.25 Altogether, this
combination of biomarkers offers complementary mecha-
nistic insights during cardiac evaluation in stable patients,
although only a small subset of patients demonstrated
positive results for all 3 biomarkers in our relatively stable
patient cohort.
Our study further explored the impact of glycemic
control on the prognostic value of cardiac biomarkers,
particularly as the latest guidelines have highlighted a subset
of “at-risk” patients that is thought to have heightened risk
for developing diabetes mellitus and future cardiovascular
risk.7,26 We observed a graded increase in the levels of each
of our corresponding biomarkers as patients were deter-
mined to have nondiabetes, prediabetes, and diabetes. The
Figure 3. Event rates for future MACEs at 3 year follow up according to
glycemic status.
Figure 2. Forest plot of unadjusted and adjusted HRs for predicting future
MACEs at 3 year follow up according to CBS according to subgroups (zero
score as reference, adjustments as in Table 3, model 1).
overall trend toward increased risk for MACEs was similar
among all groups on the basis of their CBS. Similarly, the
CBS provided signiﬁcant prognostic value among subjects
for whom no signiﬁcant angiographic evidence of stenosis
was discovered, who are most often considered to have
lower risk.
The strength of this study is the considerable size of the
patient population. This contemporary cohort of stable
cardiac patients is representative of current clinical practice.
The focus on the homogenous elective coronary angiography
population and the availability and inclusion of only
biomarkers cleared by the United States Food and Drug
Administration for the analyses strengthen the study, as the
present biomarkers, although clinically available for use, are
not routinely measured. Including them in the analysis
provides insight into a nonacute, troponin-negative pop-
ulation, which has yet to be thoroughly investigated. Incre-
mental contributions of these cardiac biomarkers toward risk
stratiﬁcation above and beyond standard clinical and
biochemical characteristics in this population have also not
been thoroughly tested, particularly with rigorous statistical
evaluation or covariate adjustments. Potential weaknesses of
the study population arise because a clinical trial cohort of
patients who underwent coronary angiography was used, and
thus resulting in, particularly because they were already
undergoing cardiac evaluation. Moreover, our data relate to
prognostic rather than diagnostic applications of these
biomarkers. We also did not have high-sensitivity troponin
assays in this cohort, which was deemed troponin negative by
currently approved troponin assays. Last, although our results
were based on previously used cut points, they may over-
estimate the strengths of the risk relations. With different
studies using different cutoff values for different popu-
lations, there is a need to identify clinically useful cut points
on the basis of consensus of results.
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